Myriad Genetics

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Myriad Genetics reports robust Q4 growth and eyes market expansion

Myriad Genetics showcased strong revenue growth and strategic initiatives to drive profitability in Q4 2022.
The company's focus on customer engagement, product volumes, and market positioning reflects a commitment to growth and operational excellence.
Challenges in managing competition and optimizing operational efficiency are balanced by opportunities for revenue growth and market expansion.

Myriad Genetics reports strong Q1 earnings, eyes profitability in Q4

Myriad Genetics demonstrated robust performance in Q1, leveraging strategic partnerships and operational improvements to drive revenue growth and enhance testing volumes.
While facing challenges like billing issues and seasonality-related declines, the company remains focused on core products, profitability, and growth opportunities.
With a strong financial outlook, emphasis on innovation, and commercial initiatives, Myriad Genetics is well-positioned to capitalize on market opportunities and drive sustainable growth.

Myriad Genetics reports solid Q2 growth and strategic focus

Myriad Genetics showcased strong financial performance, operational efficiencies, and strategic focus on growth and profitability.
While facing challenges like milestone payment concerns and industry competition, the company's strengths in key segments and operational capabilities position them well.
Opportunities in product enhancements, channel expansions, and investor engagement pave the way for continued success and market leadership.

Myriad Genetics reports strong Q3 earnings and raises 2024 guidance

Myriad Genetics reported strong revenue growth and operational improvements, with a focus on key product lines and enhancing customer experience.
The company raised financial guidance for 2023 and introduced revenue guidance for 2024, showcasing confidence in achieving long-term growth targets.
Challenges include regulatory changes, market penetration, and maintaining profitability amidst competitive dynamics, while opportunities lie in sustained growth and revenue optimization.
Overall, Myriad Genetics demonstrated resilience and strategic focus in driving growth, improving margins, and navigating market challenges effectively.

Myriad Genetics reports strong Q4 performance and eyes market expansion

Myriad Genetics delivered a strong Q4 performance with a focus on growth, strategic investments, and operational improvements. The company faces challenges in pricing and reimbursement but sees opportunities in market expansion and new product launches. Overall, Myriad Genetics is optimistic about its future prospects and market positioning.

Myriad Genetics reports robust Q1 performance and eyes growth opportunities

Myriad Genetics delivered a strong quarter with revenue growth and positive EBITDA, focusing on strategic areas like oncology and women's health. The company is optimistic about exceeding guidance but remains cautious. Analysts raised inquiries about various segments and operational decisions, with the company emphasizing profitable growth and maintaining margins.

Myriad Genetics reports strong Q2 performance and raises revenue targets

Myriad Genetics delivered a robust Q2 performance with revenue growth, positive earnings, and strategic wins in payer coverage, setting the stage for continued growth.
The company's focus on efficiency, customer satisfaction, and profitable growth positions it well for future success amidst market challenges and opportunities.
With raised revenue targets, expanded market acceptance, and operational excellence, Myriad Genetics demonstrates resilience and adaptability in a dynamic healthcare landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coronavirus testing is up, but the pandemic has hammered demand for Myriad's hereditary cancer tests.

Here's Why Myriad Genetics Is Tumbling Today

New LCD Provides Coverage for PGx Testing Across a Broad Range of Providers and Psychiatric Conditions New LCD Provides Coverage for PGx Testing Across a Broad Range of Providers and Psychiatric Conditions

Palmetto GBA Issues Final Local Coverage Determination on Pharmacogenomic Testing for Medicare Beneficiaries

Myriad Genetics' (MYGN) GeneSight Psychotropic test is shown to be superior at predicting blood concentrations unlike single-gene testing as demonstrated by a latest study.

Myriad Genetics' Test Better Predicts Drug Levels Per Study

Study Reviewed Citalopram and Escitalopram Study Reviewed Citalopram and Escitalopram

New Study Demonstrates GeneSight Psychotropic Better Predicts  Blood Drug Levels When Compared to Single-Gene Testing

Burlington Stores

Ferrari

Schlumberger

Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.

Keep These 4 Toxic Stocks Off Your Portfolio to Avoid Losses

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?

Why Is Myriad (MYGN) Up 8.9% Since Last Earnings Report?

EndoPredict Predicts Response to Neoadjuvant Chemotherapy and Endocrine Therapy EndoPredict Predicts Response to Neoadjuvant Chemotherapy and Endocrine Therapy

Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer

SALT LAKE CITY, May  29, 2020  (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced the presentation of two new studies at the 2020 American Society of Clinical Oncology (ASCO) annual meeting demonstrating the ability of Myriad’s riskScore ®  test to provide personalized breast cancer risk information that allows patients and physicians to make better informed clinical treatment decisions.

Myriad Presents New Data at ASCO Validating the Ability of riskScore®  to Provide Personalized Breast Cancer Risk Information to Patients

SALT LAKE CITY, May  28, 2020  (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announced the election of Daniel K. Spiegelman, age 61, to its Board of Directors, effective immediately, expanding the Board to nine members.  Additionally, Mr. Spiegelman was appointed to the audit committee of Myriad’s Board.

Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T.

Cinemark Holdings

IDEXX Laboratories

Vericel

Dump These 4 Toxic Stocks or Sell Short for Timely Profits

- Patients hospitalized with COVID-19 had significantly elevated levels of the inflammatory cytokine LIGHT

Cerecor and Myriad Genetics Announce that Levels of LIGHT, a Novel Cytokine, Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study

SALT LAKE CITY, May  20, 2020  (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the BRACAnalysis CDx ®  test for use as a companion diagnostic by healthcare professionals to identify men with metastatic castration-resistant prostate cancer (mCRPC) who are eligible for treatment with Lynparza® (olaparib). Lynparza is approved for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Lynparza is a novel PARP inhibitor jointly developed and commercialized by AstraZeneca (LSE/STO/NYSE: AZN) and Merck, known as MSD outside of the U.S. and Canada. 

Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer

Within Molecular Diagnostics, Myriad Genetics (MYGN) registers strong sales for EndoPredict, myChoice CDx and BRACAnalysis CDx.

Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem

Myriad's Ovarian Cancer Test Approved, And Other News: The Good, Bad And Ugly Of Biopharma

SALT LAKE CITY, May  11, 2020  (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the myChoice CDx®  test for use as a companion diagnostic by healthcare professionals to identify advanced ovarian cancer patients with positive homologous recombination deficiency (HRD) status, who are eligible or may become eligible, for first-line maintenance treatment with Lynparza (olaparib) in combination with bevacizumab. Lynparza (olaparib) is a novel PARP inhibitor jointly developed and commercialized by AstraZeneca (LSE/STO/NYSE: AZN) and Merck, known as MSD outside of the U.S. and Canada. 

Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer

Myriad Genetics (MYGN) reports revenue declines in both reporting segments in Q3 resulting from coronavirus-led business disruptions.

Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View

Myriad Genetics, Inc. (MYGN) CEO Bryan Riggsbee on Q3 2020 Results - Earnings Call Transcript

Casella Waste Systems

Penn Entertainment

SiteOne Landscape Supply

Dump or short sell these four toxic stocks from your portfolio to avoid losses.

Safeguard Your Portfolio by Abandoning These 4 Toxic Stocks

New Article Published Online in the Journal Pharmacogenomics New Article Published Online in the Journal Pharmacogenomics

Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight® Psychotropic Test in People with Major Depressive Disorder

SALT LAKE CITY, April  08, 2020  (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, announced today that due to the impact of the global COVID-19 pandemic, the company is withdrawing its fiscal year 2020 financial guidance.

Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic

Myriad Genetics (MYGN) launches BRACAnalysis Diagnostic System in Japan, after receiving reimbursement for the system, which will enable easier identification of HBOC patients.

Myriad Genetics' (MYGN) BRACAnalysis Gets Japan Reimbursement

More Than 25,000 People in Japan Are Eligible for Genetic Testing More Than 25,000 People in Japan Are Eligible for Genetic Testing

Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC

SALT LAKE CITY, March  30, 2020  (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced it has submitted a supplementary application with the Japanese Ministry of Health Labour and Welfare for its BRACAnalysis ®  Diagnostic System (i.e., “BRACAnalysis”) to be used as a companion diagnostic to help to identify people with metastatic pancreatic or metastatic castration-resistant prostate cancer who have germline BRCA1 and BRCA2 mutations and may be candidates for targeted therapy with the PARP inhibitor, Lynparza® (olaparib), subject to regulatory approval.  

Myriad Seeks Japanese Regulatory Approval for its BRACAnalysis® Diagnostic System in People with Advanced Pancreatic and Prostate Cancer

S. Louise Phanstiel Appointed Chair of the Board of Directors;     John T. Henderson, M.D., to Remain on the Board

Myriad Announces Board of Directors Leadership Transition

Exact Sciences

Invitae

Have these growth stocks bottomed out? That's probably the wrong question to ask.

News for Myriad Genetics Stock (MYGN)